Oral dabrafenib and trametinib
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Craniopharyngioma
Conditions
Craniopharyngioma
Trial Timeline
Sep 1, 2023 → Apr 10, 2028
NCT ID
NCT05525273About Oral dabrafenib and trametinib
Oral dabrafenib and trametinib is a phase 2 stage product being developed by Novartis for Craniopharyngioma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05525273. Target conditions include Craniopharyngioma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05525273 | Phase 2 | Recruiting |
Competing Products
2 competing products in Craniopharyngioma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tovorafenib | Day One Biopharmaceuticals | Phase 2 | 47 |
| peginterferon alfa-2b | Brain Biotech | Phase 2 | 44 |